Literature DB >> 11299820

Vascular integrin beta 3 and its relation to pulmonary metastasis of colorectal carcinoma.

T Sato1, K Konishi, H Kimura, K Maeda, K Yabushita, M Tsuji, A Miwa.   

Abstract

Integrin alpha v-beta 3 is involved in tumor angiogenesis while the clinical significance of beta 3 integrin expression in colorectal cancer and lung metastases. Analysis was performed on 51 colorectal cancer patients (22 with subsequent lung metastasis and 29 without lung metastasis). Fifty-one primary tumors and 22 lung metastases were examined for immunohistochemical detection of integrin beta 3. We found that the antibody VNR 5 to integrin beta 3 prefentially stains the blood vessels of small caliber. Indeed, vascular integrin beta 3 index was significantly higher in tumors of patients with lung metastasis than in those without lung metastasis. In the patients with lung metastases, vascular integrin beta 3 index was significantly lower in lung metastases than in primary tumors. It was immunohistochemically proved that integrin beta 3 is an important vascular endothelial cell market for lung metastasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11299820

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas.

Authors:  Eva-Maria Fabricius; Gustav-Paul Wildner; Ute Kruse-Boitschenko; Bodo Hoffmeister; Simon L Goodman; Jan-Dirk Raguse
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

Review 2.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

3.  Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent.

Authors:  Gabriela D'Amico; Stephen D Robinson; Mitchel Germain; Louise E Reynolds; Gareth J Thomas; George Elia; Garry Saunders; Marcus Fruttiger; Victor Tybulewicz; Georgia Mavria; Kairbaan M Hodivala-Dilke
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

4.  Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography.

Authors:  Oliver Schnell; Bjarne Krebs; Janette Carlsen; Isabelle Miederer; Claudia Goetz; Roland H Goldbrunner; Hans-Jürgen Wester; Roland Haubner; Gabriele Pöpperl; Markus Holtmannspötter; Hans A Kretzschmar; Horst Kessler; Jörg-Christian Tonn; Markus Schwaiger; Ambros J Beer
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

5.  Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis.

Authors:  Eleonora Patsenker; Yury Popov; Felix Stickel; Vreni Schneider; Monika Ledermann; Hans Sägesser; Gerald Niedobitek; Simon L Goodman; Detlef Schuppan
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

6.  One-step (18)F labeling of non-peptidic bivalent integrin αvβ3 antagonist for cancer imaging.

Authors:  Weiwei Wang; Zhiyi Liu; Zheng Li
Journal:  Bioconjug Chem       Date:  2015-01-12       Impact factor: 4.774

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.